Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: esovynd respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). esovynd respimat is indicated for the prevention of copd exacerbations.,asthma: esovynd respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - olodaterol hydrochloride, quantity: 2.7 microgram/actuation (equivalent: olodaterol, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: disodium edetate; citric acid; purified water; benzalkonium chloride - striverdi respimat is a long-acting beta2-agonist indicated for once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - melarsomine dihydrochloride (unii: 9cva716q71) (melarsomine - unii:374gj0s41a) - immiticide sterile power is indicated for the treatment of stabilized class 1a , 2b , and 3c heartworm disease caused by immature (4 month-old, stage l5 ) to mature adult infections of dirofilaria immitis in dogs. heartworm disease classification : the following parameters were used to classify the dogs in the clinical field trials for immiticide. other parameters may be considered. as a general rule, conservative treatment should be employed since heartworm disease is serious and potentially fatal. if there is evidence of a high worm burden, patients should be categorized as class 3. a class 1: patients in this category are characterized as having asymptomatic to mild heartworm disease. no radiographic signs or signs of anemia are evident. patients with mild disease may have subjective signs such as a general loss of condition, fatigue on exercise, or occasional cough; however, no objective radiographic or other abnormal laboratory parameters will be present. b class 2: patients in this category are characterized as having moderate heartworm disease. radiographic signs or signs of anemia [packed cell volume (pcv) less than 30% but greater than 20%, or other hematologic parameters below normal] are evident. mild proteinuria (2+) may be present. radiographic signs may include right ventricular enlargement, slight pulmonary artery enlargement, or circumscribed perivascular densities plus mixed alveolar/interstitial lesions. patients may be free of subjective clinical signs or may have a general loss of condition, fatigue on exercise, or occasional cough. if necessary, patients should be stabilized prior to treatment. c class 3: patients in this category are characterized as having severe heartworm disease. these patients have a guarded prognosis. subjective signs of disease may include cardiac cachexia (wasting), constant fatigue, persistent cough, dyspnea, or other signs associated with right heart failure such as ascites and/or jugular pulse. radiographic signs may include right ventricular enlargement or right ventricular plus right atrial enlargement, severe pulmonary artery enlargement, circumscribed to chronic mixed patterns and diffuse patterns of pulmonary densities or radiographic signs of thromboembolism. signs of significant anemia (pcv <20% or other hematologic abnormalities) may be present. proteinuria (>2+) may be present. patients may have only moderate clinical signs and significant laboratory or radiographic alterations or they may have significant clinical signs with only moderate laboratory and radiographic signs and be categorized as class 3. patients in class 3 should be stabilized prior to treatment and then administered the alternate dosing regime (see precautions and dosage and administration ). immiticide is contraindicated in dogs with very severe (class 4) heartworm disease. patients in this category have caval syndrome (d. immitis present in the venae cavae and right atrium).

Canada - English - Health Canada

boehringer ingelheim animal health canada inc. - esafoxolaner; eprinomectin; praziquantel - solution - 1.2%; 0.4%; 8.3% - esafoxolaner 1.2%; eprinomectin 0.4%; praziquantel 8.3% - cats

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim animal health uk ltd - foot-and-mouth disease virus - emulsion for injection - inactivated viral vaccine - cattle, goats, pigs, sheep

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim animal health uk ltd - foot-and-mouth disease virus - suspension for injection - inactivated viral vaccine - cattle, goats, sheep

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim animal health uk ltd - foot-and-mouth disease virus - emulsion for injection - inactivated viral vaccine - cattle, goats, pigs, sheep

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim animal health uk ltd - foot-and-mouth disease virus - suspension for injection - inactivated viral vaccine - cattle, goats, sheep

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - leptospirosis - dog - leptospira icterohaemorrhagiae; canine adeno virus type 2; canine coronavirus vaccine - antigen; canine distemper virus strain onderstepoort; canine parvo virus - misc. vaccines or anti sera - leptospirosis - dog - leptospira icterohaemorrhagiae vaccine active 0.0 u; canine adeno virus type 2 vaccine-viral active 0.0 u; canine coronavirus vaccine - antigen vaccine-viral active 0.0 u; canine distemper virus strain onderstepoort vaccine-viral active 0.0 u; canine parvo virus vaccine-viral active 0.0 u - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine parainfluenza; leptospira icterohaemorrhagiae antigen; canine adeno virus type 2; canine coronavirus vaccine - antigen; canine distemper virus; canine parvo virus - misc. vaccines or anti sera - canine parainfluenza vaccine active 0.0 undefined; leptospira icterohaemorrhagiae antigen vaccine-antigen active 0.0 undefined; canine adeno virus type 2 vaccine-viral active 0.0 undefined; canine coronavirus vaccine - antigen vaccine-viral active 0.0 undefined; canine distemper virus vaccine-viral active 0.0 undefined; canine parvo virus vaccine-viral active 0.0 undefined - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus